Glial-Dopamine crosstalk: Astrocytic and microglial gatekeepers of neuroinflammation, plasticity, and motivation.

AIMS neuroscience 2026
Open on PubMed

Dpamine (DA) signaling has long been framed through a neuron-centric lens; yet, mounting evidence reveals that glial cells (astrocytes and microglia) serve as indispensable gatekeepers of dopaminergic tone, synaptic plasticity, and neuroimmune balance. Single-cell, spatial, and optical imaging studies have redefined DA circuits as multicellular ecosystems in which glial receptors, transporters, and gliotransmitters dynamically sculpt neuromodulation and behavior. Astrocytes fine-tune DA clearance, glutamate buffering, and metabolic coupling, while microglia integrate immune and stress cues recalibrate dopaminergic signaling across striatal and cortical circuits. Their bidirectional interactions, both glia-glia and glia-neuron, mediate resilience or vulnerability in contexts ranging from motivation and stress adaptation to Parkinson's disease (PD), depression, and post-viral fatigue syndromes. In this review, we synthesized emerging evidence that glial-DA crosstalk is a systems-level regulator of neuroinflammation and plasticity, bridging cellular metabolism, immune tone, and behavioral output. By integrating multi-omics, in vivo imaging, and computational models, we proposed a translational framework for targeting astrocytic and microglial states to restore dopaminergic homeostasis. Understanding and manipulating these non-neuronal interfaces may open the next frontier in precision neuropsychiatry and neurodegeneration therapeutics.

5 Figures Extracted
Figure 1.
Figure 1. PMC
Astrocyte-targeted therapeutic pathways for modulating DA circuits in health and disease.
Figure 2.
Figure 2. PMC
Disorder-specific pathways of Glial-DA dysregulation and motivational dysfunction.
Figure 3.
Figure 3. PMC
Integrated glial-dopamine interaction network in health and disease.
Figure 4.
Figure 4. PMC
Emerging glial therapeutic pathways: Precision modulation of microglial and astrocytic programs in PD and related disorders.
Figure 5.
Figure 5. PMC
Glia-directed therapeutic paradigms in dopaminergic neurodegeneration.